Terutroban, a Thromboxane/Prostaglandin Endoperoxide Receptor Antagonist, Increases Survival in Stroke-Prone Rats by Preventing Systemic Inflammation and Endothelial Dysfunction: Comparison with Aspirin and Rosuvastatin
暂无分享,去创建一个
E. Tremoli | M. Brioschi | C. Banfi | A. Gianella | E. Nobili | U. Guerrini | L. Lerond | L. Castiglioni | V. Blanc-Guillemaud | L. Sironi | P. Gelosa | A. Pignieri | R. Ballerio
[1] Á. Chamorro,et al. The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline Characteristics of the Population , 2009, Cerebrovascular Diseases.
[2] T. Ishizuka,et al. Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats. , 2008, Life sciences.
[3] G. Remuzzi,et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. , 2007, The American journal of pathology.
[4] T. Ishizuka,et al. Involvement of thromboxane A2 receptor in the cerebrovascular damage of salt-loaded, stroke-prone rats , 2007, Journal of hypertension.
[5] A. Heidland,et al. Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes , 2007, Diabetes.
[6] E. Tremoli,et al. Gender differences in endothelial function and inflammatory markers along the occurrence of pathological events in stroke-prone rats. , 2007, Experimental and molecular pathology.
[7] Mengwei Zang,et al. The Thromboxane A2 Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus , 2005, Circulation.
[8] Julie H. Campbell,et al. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. , 2005, Atherosclerosis.
[9] V. Fuster,et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. , 2005, European heart journal.
[10] E. Johns,et al. Effect of COX inhibitors and NO on renal hemodynamics following ischemia-reperfusion injury in normotensive and hypertensive rats. , 2005, American journal of physiology. Renal physiology.
[11] E. Tremoli,et al. Rosuvastatin, but not Simvastatin, Provides End-Organ Protection in Stroke-Prone Rats by Antiinflammatory Effects , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[12] E. Benjamin,et al. Brachial Artery Vasodilator Function and Systemic Inflammation in the Framingham Offspring Study , 2004, Circulation.
[13] M. Wolzt,et al. Simvastatin Prevents Vascular Hyporeactivity During Inflammation , 2004, Circulation.
[14] J. Keaney,et al. The clinical implications of endothelial dysfunction. , 2003, Journal of the American College of Cardiology.
[15] Juan Yu,et al. [Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats]. , 2003, Yao xue xue bao = Acta pharmaceutica Sinica.
[16] G. Pelle,et al. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. , 2003, Journal of the American College of Cardiology.
[17] T. Grosser,et al. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.
[18] B. Pollo,et al. New Insights Into Brain Damage in Stroke-Prone Rats: A Nuclear Magnetic Imaging Study , 2002, Stroke.
[19] E. Tremoli,et al. Acute-Phase Proteins Before Cerebral Ischemia in Stroke-Prone Rats: Identification by Proteomics , 2001, Stroke.
[20] R. Cohen,et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[21] A. Kurita,et al. Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein‐1 (MCP‐1) expression by stimulated vascular endothelial cells , 2000, Clinical and experimental immunology.
[22] G. Lavielle,et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. , 1998, Bioorganic & medicinal chemistry letters.
[23] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[24] E. Tremoli,et al. S 18886, a thromboxane A2 receptor antagonist, prevents occurrence of spontaneous brain damage in stroke-prone rats via anti-inflammatory activities , 2007 .
[25] Jiali Gu,et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. , 2006, Diabetes.
[26] A. Huang,et al. Effects of systemic inflammation on endothelium-dependent vasodilation. , 2006, Trends in cardiovascular medicine.